ZMYND8在成人胶质瘤患者中的表达及其预后价值

doi:10.3969/j.issn.1004-616x.2025.01.009

Abstract

Abstract: OBJECTIVE： To investigate the expression and prognostic value of subtype 8 of the zinc finger domain containing myeloid neurodegenerative epidermal growth factor (ZMYND8) in adult glioma. METHODS： Immunohistochemistry was used to detect the expression level of ZMYND8 in 104 adult glioma tissues， and the relationship between ZMYND8 expression and prognosis of glioma patients was evaluated by receiver operating characteristic (ROC) curve prediction efficiency. Kaplan-Meier survival was used to analyze the relationship between ZMYND8 expression and overall survival (OS) of adult human glioma patients. Cox regression was used to analyze factors affecting the survival of patients with glioma after surgery. RESULTS： The immunohistochemical results showed that the expression of ZMYND8 protein in glioma was higher than that in normal brain tissue (P<0.05)，and the high expression rate in high-grade glioma was significantly higher than that in low-grade glioma (P<0.05). The expression of ZMYND8 was correlated with pathological classification and WHO grade (P<0.01)，but not with sex，age，tumor site，tumor diameter，and Karnofsky (KPS) score. Kaplan-Meier survival analysis showed that the OS of glioma patients with high expression of ZMYND8 was significantly lower than that of glioma patients with low expression (Log-rank P<0.01). Multivariate Cox regression analysis showed that age and WHO grade were independent factors of glioma OS. CONCLUSION： The expression of ZMYND8 was increased in adult glioma patients and the increase was related to the degree of malignancy and prognosis. Thus，ZMYND8 can be used as a potential marker for the diagnosis and prognosis of glioma.

Key words: adult glioma, WHO, immunohistochemistry, zinc finger MYND-type containing 8, prognosis

CLC Number:

R739.4

XIAO Huanqin, XIE Shoucheng, ZHONG Ying, LUO Wenjuan, HUANG Yanfang, LUO Haiyan, YU Qiuzhu, ZHU Wenbiao. ZMYND8 as a novel diagnostic and prognostic biomarker for glioma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 52-55,62.

References

[1] HORBINSKI C, BERGER T, PACKER R J, et al. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours[J]. Nat Rev Neurol, 2022, 18(9): 515-529.
[2] LAPOINTE S, PERRY A, BUTOWSKI N A. Primary brain tumours in adults[J]. Lancet, 2018, 392(10145): 432-446.
[3] STURM D, PFISTER S M, JONES D T W. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management[J]. J Clin Oncol, 2017, 35(21): 2370-2377.
[4] CHEN Y, TSAI Y H, TSENG S H. Regulation of ZMYND8 to treat cancer[J]. Molecules, 2021, 26(4): 1083.
[5] GONG F D, CHIU L Y, COX B, et al. Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination[J]. Genes Dev, 2015, 29(2): 197-211.
[6] CHEN J W, HE Q M, WU P S, et al. ZMYND8 expression combined with pN and pM classification as a novel prognostic prediction model for colorectal cancer: based on TCGA and GEO database analysis[J]. Cancer Biomark, 2020, 28(2): 201-211.
[7] PAN Q, ZHONG S S, WANG H L, et al. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability[J]. Mol Cell, 2021, 81(13): 2736-2751.e8.
[8] CHEN J W, LIU J, CHEN X T, et al. Low expression of ZMYND8 correlates with aggressive features and poor prognosis in nasopharyngeal carcinoma[J]. Cancer Manag Res, 2019, 11: 7835-7843.
[9] 李博伟, 王胜, 卓扬佳, 等. 锌指含髓样神经变形表皮生长因子结构域第8亚型作为糖皮质激素受体下游基因在前列腺癌组织的表达及临床意义[J]. 中华实验外科杂志, 2017, 34(8): 1405-1407.
[10] LOUIS D N, PERRY A, WESSELING P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[11] KANU O O, MEHTA A, DI C H, et al. Glioblastoma multiforme: a review of therapeutic targets[J]. Expert Opin Ther Targets, 2009, 13(6): 701-718.
[12] LARA-VELAZQUEZ M, AL-KHARBOOSH R, JEANNERET S, et al. Advances in brain tumor surgery for glioblastoma in adults[J]. Brain Sci, 2017, 7(12): 166.
[13] LUDWIG K, KORNBLUM H I. Molecular markers in glioma[J]. J Neurooncol, 2017, 134(3): 505-512.
[14] KUROYANAGI J, SHIMADA Y, ZHANG B B, et al. Zinc finger MYND-type containing 8 promotes tumour angiogenesis via induction of vascular endothelial growth factor-a expression[J]. FEBS Lett, 2014, 588(18): 3409-3416.
[15] LAI A Y, WADE P A. Cancer biology and NuRD: a multifaceted chromatin remodelling complex[J]. Nat Rev Cancer, 2011, 11: 588-596.
[16] 刘长兵, 姚丰, 牛多山, 等. 胃癌组织中ZMYND8蛋白的表达及临床病理学意义[J]. 承德医学院学报, 2020, 37(4): 271-275.
[17] SACHDEV S, DMELLO C, SONABEND A M. Radiosensitization of IDH-mutated gliomas through ZMYND8-a pathway to improved outcomes[J]. Clin Cancer Res, 2023, 29(9): 1648-1650.
[18] CARNEY S V, BANERJEE K, MUJEEB A, et al. Zinc finger MYND-type containing 8(ZMYND8) is epigenetically regulated in mutant isocitrate dehydrogenase 1(IDH1) glioma to promote radioresistance[J]. Clin Cancer Res, 2023, 29(9): 1763-1782.
[19] 朱文标, 卢善明, 李海南, 等. 联合IDH1、1p/19q和ATRX对胶质瘤分子分型的临床意义[J]. 南昌大学学报: 医学版, 2020, 60(4): 41-45.

ZMYND8 as a novel diagnostic and prognostic biomarker for glioma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	SHI Minjie, LI Jiawei, GUO Xiaojie, WANG Changyan, FAN Zhenpeng, LIU Jiangzheng, LI Wenli, KONG Deqin, XIN Bao. Effect of aerosol inhalation of a blister agent 2-chloroethyl ethyl sulfide on pulmonary function in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 27-32,38.
[2]	GUO Xujuan, JIA Yuming, YAN Xi, ZHAO Hongzheng, GUO Yiyang, ZHANG Jinyan. Clinical value of CST4 in auxiliary diagnosis and prognosis assessment of pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 463-469.
[3]	KANG Xiaopei, GUO Zhenjiang, LIU Fangzhen. The expression and prognosis of BAF57 in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 379-383.
[4]	ZHU Wenbiao, YAN Chunmei, QIU Bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression of secreted frizzled-related protein 4 in hepatocellular carcinoma, and relationship with clinicopathological index and prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 288-293,297.
[5]	MA Sheng, WANG Xijun, LIU Zhenrong, WANG Yaru, HU Nan, RONG Weiqi, XIAO Ting. The expression and clinical significance of MFSD2A in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 187-194.
[6]	ZHANG Yi, GAO Han, ZHENG Zhanyue, TAN Qitao, YANG Minli, SUN Yan. Screening of key genes for prognosis of glioma based on public databases [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 195-201.
[7]	SONG Zhenming, YU Yunliang, YANG Jinmei, LIU Kun, GAI Chanchan, MA Chunyu. Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 208-218.
[8]	WANG Ziyi, LIU Hao, WU Dongyang, ZHAO Chunxia. Evaluating the clinical application of computational methods for identifying splice variants in cardiomyopathy-associated genes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 85-93.
[9]	FU Yongqing, XU Sanhui, ZHAO Yan, WANG Lili. Relationships between SPP1, DEC1, C1QTNF6 and clinicopathologic outcomes of oral squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 107-111,117.
[10]	TONG Jing, WANG Dan. Expression and significance of miR-544a in patients with colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 124-128,137.
[11]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[12]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[13]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[14]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[15]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.